期刊文献+

骨形成发生蛋白4在胶质瘤细胞株U251中的作用 被引量:4

Role of bone morhogenetic proteins 4 in the human brain glioma cell line U251
原文传递
导出
摘要 目的 观察骨形成发生蛋白4(BMP4)在U251细胞中的作用.方法 阿霉素、BMP4质粒体分别给予U251细胞,BMP4的小干扰给予阿霉素处理过48h的U251细胞,逆转录-聚合酶链反应(RT-PCR)、荧光定量PCR和Western blot检测转染是否成功及BMP4的表达量.噻唑蓝(MTT)检测细胞活性,应用公式(1-处理组A/空白组A)×100%计算处理组细胞增长抑制率.结果 RT-PCR、荧光定量PCR和Western blot证明转染是成功的.在给予BMP4质粒体0.5、1.0、1.5、2.0、2.5μg/孔后,细胞的抑制率分别为(23.4±1.1)%、(54.8±1.3)%、(58.8±1.6)%、(57.2±1.4)%、(56.1±0.9)%(P〈0.05),0.5μg/孔与1.0、1.5、2.0、2.5 μg/孔的抑制率差异有统计学意义(P〈0.05),1.0、1.5、2.0、2.5μg/孔之间差异无统计学意义(P〉0.05).单用阿霉素对U251细胞的抑制率为(45.2±1.1)%(P〈0.05).给予阿霉素后给予BMP4的siRNA,细胞的抑制率为(23.1±2.7)%,与阿霉素组比较差异有统计学意义(P〈0.05).结论 BMP4可以抑制胶质瘤细胞U251的生长. Objective To to investigate the role of bone morhogenetic proteins 4 (BMP4) in the human brain glioma cell line U251. Methods Adriamycin or plasmid of BMP4 was given to U251 cells, and BMP4 siRNA was given to U251 cells which had been given adriamycin for 48 h. Methyl thiazolyl tet-razolium ( MTT) was used to measure the activity of U251 cell growth in control group and treatment group. By the formula (1-Atreatment group/Acontrol group) ×100% , U251 cells growth inhibition rate was calculated. By using reverse transcription-polymerase chain reaction ( RT-PCR) , fluorescence quantitative PCR (FQ-PCR) and Western blotting, the transfection efficiency and the expression of BMP4 were assayed. Results Transfection was proved to be successful by RT-PCR, quantitative fluorescent PCR and Western blotting. Growth inhibition rate of U251 cells which were given BMP4 plasmid was (23.4± 1.1)%, (54.8±1.3)%, (58.8 ±1.6)%,(57.2 ±1.4)%, (56.1±0.9)% at the 0.5, 1.0, 1.5, 2. 0, 2. 5μg/well. There was significant difference in inhibition rate between 0. 5μg/well group and 1.0, 1.5, 2.0, 2.5μg/well groups (P〈0.05), but no significant difference was found among 1.0, 1.5, 2.0, 2.5μg/well groups (P〉0.05). After adriamycin was added to U251 cells, the inhibition rate was (45. 2 ± 1. 1) % (P 〈0. 05 ). After BMP4 siRNA was added to U251 cells which had been given adriamycin , the inhibition rate of cells was (23.1± 2.7) % (P〈0.05). Conclusion BMP4 can inhibit the glioma cells U251. BMP4 may be a new target for glioma therapy.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2010年第7期917-919,共3页 Chinese Journal of Experimental Surgery
基金 基金项目:国家自然科学基金资助项目(30772223)
关键词 骨形成发生蛋白4 靶向治疗 胶质瘤 Bone morphogenetic protein 4 Target therapy Glioma
  • 相关文献

参考文献22

  • 1Ducy P,Karsenty G.The family of bone morphogenetic proteins.Kidney Int,2000,57:2207-2214. 被引量:1
  • 2Takae R,Matsunaga S,Origuchi N,et al.Immunolocalization of bone morphogenetic proteinand its receptors in degeneration of interverte-bral disc.Spine,1999,24:1397-1401. 被引量:1
  • 3Sakou T.Bone morphogenetic proteins:from basic studies to clinical approaches.Bone,1998 22:591-603. 被引量:1
  • 4Dongmei S,Shan Z,Xuefang H,et al.BMP4-Smad signal pathway mediates Adriamycin-induced premature senescence in lung cancer cells.J Biol Chem,2009,284:12153-12164. 被引量:1
  • 5Kim ES,Khuri FR,Herbst RS.Epidermal growth factor receptor biology (IMC-C225).Curr Opin Oncol,2001,13:506-513. 被引量:1
  • 6Rodney BL,Andrew HK,Hong-Jian Z.Transforming growth factor-beta (TGF-p) and brain tumours.Journal of Clinical Neuroscience,2008,15:845-855. 被引量:1
  • 7Wong ML,Kaye AH,Hovens CM.Targeting malignant glioma survival signalling to improve clinical outcomes.J Clin Neurosci,2007,14:301-308. 被引量:1
  • 8Draker BJ,Talpaz M,Resta DJ,et al.Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med,2001,344:1031-1037. 被引量:1
  • 9O'Brien SG,Cuilhot F,Larson RA,et al.Imatinib compared with in-teiferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med,2003,348:994-1004. 被引量:1
  • 10Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med,2001,344:783-792. 被引量:1

二级参考文献27

共引文献17

同被引文献5

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部